Study to Evaluate the Therapeutic Equivalence of SYN008 Versus Xolair® in the Treatment of Patients With Refractory Chronic Spontaneous Urticaria

NCT04944602 · clinicaltrials.gov ↗

PHASE3

Phase

UNKNOWN

Status

340

Enrollment

INDUSTRY

Sponsor class

Conditions

Chronic Spontaneous Urticaria

Interventions

BIOLOGICAL: SYN008
BIOLOGICAL: Omalizumab for injection

Sponsor

CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.